Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics

Abiraterone acetate (AA) has been proven effective for metastatic castration-resistant prostate cancer (mCRPC), and it has been proposed that adaptive AA may reduce toxicity and prolong time to progression, when compared to continuous AA. We developed a simple quantitative model of prostate-specific...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neoplasia
Hlavní autoři: Brady-Nicholls, Renee, Zhang, Jingsong, Zhang, Tian, Wang, Andrew Z., Butler, Robert, Gatenby, Robert A., Enderling, Heiko
Médium: Artigo
Jazyk:Inglês
Vydáno: Neoplasia Press 2021
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8322456/
https://ncbi.nlm.nih.gov/pubmed/34298234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2021.06.013
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky